The present invention provides a gene-targeted, non-human mammal having a
gene encoding a mutant protein product of a mutated FAD presenilin-1
(PS-1) gene, a human FAD Swedish mutation, and a humanized A.beta.
mutation, and generational offspring thereof and a gene-targeted,
non-human mammal having a gene encoding a mutant protein product of a
mutated FAD PS-1 gene and a human Swedish APP695 mutation, and
generational offspring thereof, as well as methods of identifying
compounds useful in treating Alzheimer's disease, and to methods of
treating Alzheimer's disease.
